Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

ACADIA Pharmaceuticals Inc. (ACAD): Are Hedge Funds Right About This Stock?

Page 1 of 2

Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback the hedge funds employing these talents and can benefit from their vast resources and knowledge in that way. We analyze quarterly 13F filings of over 700 hedge funds and, by looking at the smart money sentiment that surrounds a stock, we can determine whether it has potential to beat the market over the long-term. Therefore, let’s take a closer look at what smart money thinks about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) undervalued? The smart money is taking a pessimistic view. The number of bullish hedge fund positions were cut by 2 lately. At the end of this article we will also compare ACAD to other stocks including Owens-Illinois Inc (NYSE:OI), Companhia Brasileira de Distrib. (ADR) (NYSE:CBD), and Radian Group Inc (NYSE:RDN) to get a better sense of its popularity.

Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)
Trade (NASDAQ:ACAD) Now!

With all of this in mind, we’re going to go over the recent action encompassing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

How have hedgies been trading ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

At Q3’s end, a total of 24 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -8% from the previous quarter. With the smart money’s sentiment swirling, there exists a select group of key hedge fund managers who were increasing their holdings considerably (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Julian Baker and Felix Baker’s Baker Bros. Advisors has the largest position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), worth close to $677.3 million, amounting to 6.3% of its total 13F portfolio. Sitting at the No. 2 spot is Steve Cohen of Point72 Asset Management, with a $66.5 million position; the fund has 0.5% of its 13F portfolio invested in the stock. Some other peers that are bullish comprise Ken Griffin’s Citadel Investment Group, Jacob Gottlieb’s Visium Asset Management and Israel Englander’s Millennium Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!